Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Theriva Biologics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TOVX
American
8731
https://therivabio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Theriva Biologics Inc
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
- Apr 8th, 2024 12:00 pm
Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript
- Mar 26th, 2024 12:42 pm
Q4 2023 Theriva Biologics Inc Earnings Call
- Mar 26th, 2024 2:38 am
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
- Mar 25th, 2024 11:30 am
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
- Mar 19th, 2024 12:00 pm
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
- Mar 11th, 2024 12:00 pm
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
- Feb 7th, 2024 1:00 pm
Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference
- Jan 16th, 2024 1:00 pm
Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now
- Dec 5th, 2023 12:00 pm
Theriva Biologics, Inc. (NYSE:TOVX) Q3 2023 Earnings Call Transcript
- Nov 20th, 2023 10:56 pm
Q3 2023 Theriva Biologics Inc Earnings Call
- Nov 14th, 2023 8:14 am
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
- Nov 13th, 2023 1:00 pm
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results
- Nov 6th, 2023 9:05 pm
Theriva™ Biologics to Participate in the BIO-Europe Conference
- Nov 2nd, 2023 8:15 pm
Theriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer
- Nov 2nd, 2023 12:00 pm
Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now
- Nov 1st, 2023 11:00 am
Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023
- Oct 23rd, 2023 11:00 am
Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- Oct 16th, 2023 12:00 pm
Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now
- Oct 4th, 2023 11:00 am
Theriva Biologics to Participate in the Emerging Growth Conference
- Sep 28th, 2023 12:00 pm
Scroll